Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

615
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
615
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Navigating luminal heterogeneity: etiology-based proteogenomic subtyping for targeted treatment strategies in breast cancer.

Molecular cancer·2026
Same author

The Role of Videoconferencing Teleconsultation in Improving Transfer Efficiency and Functional Outcomes in Rural Stroke Care: Retrospective Cohort Study.

JMIR mHealth and uHealth·2026
Same author

Dual-Phase Computed Tomography-Based Deep Learning Architecture for Three-Year Survival Prediction in Hepatocellular Carcinoma.

Journal of imaging informatics in medicine·2026
Same author

Rapid Electrochemical Profiling of Fecal Short-Chain Fatty Acids Using Esterification/Dissociation Fingerprints and Artificial Neural Networks.

Biosensors·2026
Same author

Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Blood advances·2026
Same author

<i>Erratum</i> to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Haematologica·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Aug 10, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

706

CAR-T: What Is Next?

Yi-Ju Chen1, Bams Abila1, Yasser Mostafa Kamel1

  • 1School of Cancer & Pharmaceutical Sciences, Faculty of Life & Sciences & Medicine, King's College, London SE1 9NH, UK.

Cancers
|February 11, 2023
PubMed
Summary
This summary is machine-generated.

Chimeric antigen receptor-T (CAR-T) therapy shows promise for blood cancers but faces challenges like relapse and side effects. Ongoing research explores new strategies, including next-generation CAR-T cells, to improve treatment efficacy and safety.

Keywords:
CAR macrophages (CAR-Ms)CAR-NKCAR-T therapyCAR-natural killerchimeric antigen receptor-t

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

Related Experiment Videos

Last Updated: Aug 10, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

706
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • The FDA approved the first CAR-T therapies in 2017 for specific B-cell lymphomas and leukemias.
  • CAR-T therapy has shown efficacy but faces limitations including patient relapse and side effects like cytokine release syndrome (CRS).

Purpose of the Study:

  • To review advancements in CAR-T treatment strategies for hematologic malignancies.
  • To discuss clinical trials focused on enhancing CAR-T therapy efficacy and managing side effects.
  • To explore challenges and ongoing research for CAR-T therapy in solid tumors.

Main Methods:

  • Review of current literature on CAR-T therapy advancements.
  • Analysis of clinical trial data for efficacy and safety outcomes.
  • Examination of novel CAR-T approaches, including CAR-NK and CAR-Ms.

Main Results:

  • Relapse occurs in up to 60% of patients, and side effects like CRS are significant concerns.
  • New strategies include modified administration schedules, combination therapies, and next-generation CAR-T cells (CAR-NK, CAR-Ms).

Conclusions:

  • CAR-T therapy holds significant potential but requires further optimization to overcome limitations in efficacy and safety.
  • Continued research into novel CAR-T strategies and solid tumor applications is crucial for expanding its therapeutic reach.